

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

Syk Antibody

RRID:AB_2197223

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2712, RRID:AB_2197223

Antibody Information

URL: http://antibodyregistry.org/AB_2197223

Proper Citation: Cell Signaling Technology Cat# 2712, RRID:AB_2197223

Target Antigen: Syk

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation on 11/2018: AB_10691458, AB_10828107, AB_2197223.

Antibody Name: Syk Antibody

Description: This polyclonal targets Syk

Target Organism: h, m, mouse, human

Antibody ID: AB_2197223

Vendor: Cell Signaling Technology

Catalog Number: 2712

Record Creation Time: 20250820T021621+0000

Record Last Update: 20250820T130903+0000

Ratings and Alerts

No rating or validation information has been found for Syk Antibody.

No alerts have been found for Syk Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. *Immunity*, 58(6), 1572.

Fremuth LE, et al. (2025) Neuraminidase 1 regulates neuropathogenesis by governing the cellular state of microglia via modulation of Trem2 sialylation. *Cell reports*, 44(1), 115204.

Geng S, et al. (2024) Resolving neutrophils through genetic deletion of TRAM attenuate atherosclerosis pathogenesis. *iScience*, 27(6), 110097.

Luo G, et al. (2024) A human commensal-pathogenic fungus suppresses host immunity via targeting TBK1. *Cell host & microbe*, 32(9), 1536.

Zhang Q, et al. (2024) Decoding sunitinib resistance in ccRCC: Metabolic-reprogramming-induced ABAT and GABAergic system shifts. *iScience*, 27(7), 110415.

Wu Y, et al. (2024) Alleviation of monocyte exhaustion by BCG derivative mycolic acid. *iScience*, 27(2), 108978.

Wang Q, et al. (2024) Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer. *Journal of experimental & clinical cancer research : CR*, 43(1), 224.

Liu PY, et al. (2023) Infiltrating myeloid cell-derived properdin markedly promotes microglia-mediated neuroinflammation after ischemic stroke. *Journal of neuroinflammation*, 20(1), 260.

Hinke DM, et al. (2022) Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses. *Cell reports*, 39(9), 110901.

Alam A, et al. (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. *Cancer cell*, 40(2), 153.

Oh S, et al. (2022) Pathogen size alters C-type lectin receptor signaling in dendritic cells to influence CD4 Th9 cell differentiation. *Cell reports*, 38(13), 110567.

Lazarian G, et al. (2021) A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. *Cancer cell*, 39(3), 380.

Nguyen GT, et al. (2021) Neutrophils require SKAP2 for reactive oxygen species production following C-type lectin and *Candida* stimulation. *iScience*, 24(8), 102871.

Paavola KJ, et al. (2021) The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells. *Cancer immunology research*, 9(11), 1283.

Hunto ST, et al. (2020) Loratadine, an antihistamine drug, exhibits anti-inflammatory activity through suppression of the NF- κ B pathway. *Biochemical pharmacology*, 177, 113949.

Lai JJ, et al. (2020) Immune Sensing of Cell Death through Recognition of Histone Sequences by C-Type Lectin-Receptor-2d Causes Inflammation and Tissue Injury. *Immunity*, 52(1), 123.

Nguyen GT, et al. (2020) SKAP2 is required for defense against *K. pneumoniae* infection and neutrophil respiratory burst. *eLife*, 9.

Matsumura T, et al. (2019) Sequential Sensing by TLR2 and Mincle Directs Immature Myeloid Cells to Protect against Invasive Group A Streptococcal Infection in Mice. *Cell reports*, 27(2), 561.

Chiche J, et al. (2019) GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. *Cell metabolism*, 29(6), 1243.

Gui F, et al. (2019) A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies. *British journal of pharmacology*, 176(23), 4491.